GUIDELINES - The Endocrine Society

AcknowledgmentsIn addition to the members of the Task Force, there have been a number of people whose contribution to theseguidelines has been invaluable. First, we would like to thank Dr. Robert Vigersky, the members of the ClinicalGuidelines Subcommittee, the Clinical Affairs Core Committee, and the Council of The Endocrine Society fortheir careful reading of and very useful suggestions for improving the guidelines. Second, we thank the membersof The Endocrine Society at large for their input when the draft guidelines were posted on the Society’s website;all the responses received were considered by the authors, and many incorporated. Third, we thank the membersof our sister societies around the world for their enthusiastic involvement in reading the draft guidelines, and inoffering their support for this publication. Fourth, we thank Lisa Marlow of The Endocrine Society, who hasprovided first-class administrative and logistic back-up, without which such a geographically disperse task forcewould have faced considerable difficulty in operating. Last, but very much not least, the authors are indebted toDr. Patricia A. Stephens, medical writer, for her unfailing patience, her meticulous checking of both text andreferences, and most importantly her ability to meld half a dozen disparate writing styles into a seamless whole.Financial Disclosure of Task ForceTHE ENDOCRINE SOCIETY’S CLINICAL GUIDELINESJohn W. Funder, MD, PhD (chair)—Financial or Business/Organizational Interests: Schering-Plough, Daiichi-Sankyo, Pfizer, Cancer Institute of N.S.W, Speedel, Garnett Passe and Rodney Williams Memorial Foundation,Merck, Eli Lilly, P3 Panel (Commonwealth of Australia); Significant Financial Interest or Leadership Position:Schering-Plough, Pfizer, Daiichi-Sankyo and Cancer Institute of N.S.W. Robert M. Carey, MD—Financial orBusiness/Organizational Interests: Novartis, Pfizer, Daiichi-Sankyo; Significant Financial Interest or LeadershipPosition: none declared. Carlos Fardella, MD—Financial or Business/Organizational Interests: National Fund forScientific and Technological Development (Fondo Nacional de Desarrollo Científico y Tecnológico[FONDECYT]); Significant Financial Interest or Leadership Position: none declared. Celso E. Gomez-Sanchez,MD—Financial or Business/Organizational Interests: American Heart Association; Significant Financial Interestor Leadership Position: Associate Editor for the journal Hypertension. Franco Mantero, MD, PhD—Financial orBusiness/Organizational Interests: none declared; Significant Financial Interest or Leadership Position: ExecutiveCommittee of the International Society of Endocrinology. Michael Stowasser, MBBS, FRACP, PhD—Financialor Business/Organizational Interests: none declared; Significant Financial Interest or Leadership Position: nonedeclared. William F. Young Jr., MSc, MD—Financial or Business/Organizational Interests: none declared;Significant Financial Interest or Leadership Position: Mayo Clinic, Clinical Endocrinology. *Victor M. Montori,MD—Financial or Business/Organizational Interests: KER Unit (Mayo Clinic); Significant Financial Interest orLeadership Position: none declared.*Evidence-based reviews for this guideline were prepared under contract with The Endocrine Society.26